ARNA Stock: Arena Pharmaceuticals, Inc Reaches $32.43 52-Week High; La-z-boy Has 0.85 Sentiment

0
62

The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) hit a new 52-week high and has $33.73 target or 4.00% above today’s $32.43 share price. The 9 months bullish chart indicates low risk for the $1.27 billion company. The 1-year high was reported on Dec, 26 by Barchart.com. If the $33.73 price target is reached, the company will be worth $50.92M more. The stock increased 2.34% or $0.74 during the last trading session, reaching $32.43. About 61,665 shares traded. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has declined 11.92% since December 26, 2016 and is downtrending. It has underperformed by 28.62% the S&P500.

La-Z-Boy Incorporated manufactures, markets, imports, exports, distributes, and retails upholstery furniture products, accessories, and casegoods furniture products in the United States, Canada, and internationally. The company has market cap of $1.51 billion. It operates through Upholstery, Casegoods, and Retail divisions. It has a 18.27 P/E ratio. The Upholstery segment makes and imports upholstered furniture, such as recliners and motion furniture, sofas, loveseats, chairs, sectionals, modulars, ottomans, and sleeper sofas.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company has market cap of $1.27 billion. The companyÂ’s proprietary investigational clinical programs include etrasimod , which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn’s disease. It currently has negative earnings. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH.

Analysts await Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to report earnings on March, 13. They expect $-0.64 earnings per share, down 140.00% or $2.24 from last year’s $1.6 per share. After $-0.65 actual earnings per share reported by Arena Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -1.54% EPS growth.

Among 7 analysts covering Arena Pharmaceuticals (NASDAQ:ARNA), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Arena Pharmaceuticals has $5300 highest and $2 lowest target. $23.17’s average target is -28.55% below currents $32.43 stock price. Arena Pharmaceuticals had 13 analyst reports since October 28, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Tuesday, August 8 by Needham. The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has “Sector Perform” rating given on Wednesday, November 11 by RBC Capital Markets. The firm earned “Buy” rating on Wednesday, October 28 by WallachBeth Capital. FBR Capital initiated the shares of ARNA in report on Thursday, September 15 with “Outperform” rating. The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has “Buy” rating given on Thursday, June 29 by Cantor Fitzgerald. The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has “Buy” rating given on Wednesday, July 12 by Citigroup. The firm has “Buy” rating given on Tuesday, July 11 by Cantor Fitzgerald. Cantor Fitzgerald maintained Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on Wednesday, July 19 with “Buy” rating. The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) earned “Buy” rating by Leerink Swann on Monday, July 17. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, November 8 report.

Botty Investors Llc holds 4.65% of its portfolio in La-Z-Boy Incorporated for 542,726 shares. Smith Graham & Co. Investment Advisors Lp owns 352,702 shares or 0.99% of their US portfolio. Moreover, Monroe Bank & Trust Mi has 0.97% invested in the company for 91,820 shares. The Illinois-based Skyline Asset Management Lp has invested 0.91% in the stock. Regal Investment Advisors Llc, a Michigan-based fund reported 116,451 shares.

The stock increased 0.63% or $0.2 during the last trading session, reaching $31.85. About 18,597 shares traded. La-Z-Boy Incorporated (LZB) has risen 10.10% since December 26, 2016 and is uptrending. It has underperformed by 6.60% the S&P500.

Analysts await La-Z-Boy Incorporated (NYSE:LZB) to report earnings on February, 20. They expect $0.45 EPS, down 4.26% or $0.02 from last year’s $0.47 per share. LZB’s profit will be $21.29M for 17.69 P/E if the $0.45 EPS becomes a reality. After $0.47 actual EPS reported by La-Z-Boy Incorporated for the previous quarter, Wall Street now forecasts -4.26% negative EPS growth.

LEAVE A REPLY

Please enter your comment!
Please enter your name here